PAX5 and diffuse large B-cell lymphoma: In contrast, within the DLBCL non-responders, only a transient decrease of several B-cell related markers (IGHM, PAX5, CD22, POU2AF1) was noted when comparing the diagnostic samples to the interim samples, no DAG could be identified between the diagnostic and the R/R samples, and no transient increase in inflammation associated markers was noted.